Lilly ICOS LLC to Release Financial Results for 2006

  
    
  
  
    
      Lilly ICOS LLC (Lilly ICOS) (NYSE:LLY) (Nasdaq:ICOS) will announce its 
      fourth quarter and 2006 full year financial results after the U.S. 
      markets close on January 18, 2007.
    
    
      About Lilly
    
    
      Lilly, a leading innovation-driven corporation, is developing a growing 
      portfolio of first-in-class and best-in-class pharmaceutical products by 
      applying the latest research from its own worldwide laboratories and 
      from collaborations with eminent scientific organizations. Headquartered 
      in Indianapolis, Ind., Lilly provides answers - through medicines and 
      information - for some of the world's most urgent medical needs. 
      Additional information about Lilly is available at www.lilly.com. 
      F-LLY
    
    
      About ICOS
    
    
      ICOS Corporation, a biotechnology company headquartered in Bothell, 
      Washington, is dedicated to bringing innovative therapeutics to 
      patients. Through Lilly ICOS LLC, ICOS is marketing its first product, 
      Cialis(R) (tadalafil)1, 
      for the treatment of erectile dysfunction. ICOS is working to develop 
      treatments for serious unmet medical needs such as benign prostatic 
      hyperplasia, pulmonary arterial hypertension, cancer, psoriasis and 
      inflammatory diseases.
    
    
      Except for historical information contained herein, this press release 
      contains forward-looking statements within the meaning of the Private 
      Securities Litigation Reform Act of 1995. Such forward-looking 
      statements are based on current expectations, estimates and projections 
      about the industry, management beliefs and certain assumptions made by 
      the managements of ICOS and Lilly. Investors are cautioned that matters 
      subject to forward-looking statements involve risks and uncertainties, 
      including economic, competitive, governmental, technological, legal and 
      other factors discussed in the two companies’ 
      respective filings with the Securities and Exchange Commission, which 
      may affect the business and prospects of the two companies and Lilly 
      ICOS. Results and the timing and outcome of events may differ materially 
      from those expressed or implied by the forward-looking statements in 
      this press release. More specifically, there can be no assurance that 
      Cialis will achieve sustained commercial success or that competing 
      products will not pre-empt market opportunities that might exist for the 
      product.
    
    
      The forward-looking statements contained in this press release represent 
      ICOS’ and Lilly’s 
      judgments as of the date of this release. Neither ICOS nor Lilly 
      undertake any obligation to update any forward-looking statements.
    
    
      1 Cialis® is a 
      registered trademark of Lilly ICOS LLC.